Long-term trends in susceptibility of Moraxella catarrhalis: A population analysis

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 2, 2000, Pages 175-182

  Walker, E S ^a,b   Neal, C L ^b   Laffan, E ^b   Kalbfleisch, J H ^b   Berk, S L ^a,b   Levy, F ^b  

^a James H Quillen VA Medical Center   (United States)

^b East Tennessee State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BETA LACTAM; BETA LACTAMASE; CEFAMANDOLE; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; COTRIMOXAZOLE; IMIPENEM; PENICILLIN G; SULFAMETHOXAZOLE; TETRACYCLINE; TRIMETHOPRIM;

ANTIBIOTIC SENSITIVITY; ARTICLE; CORRELATION FUNCTION; GRAM NEGATIVE INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; POPULATION RESEARCH; RETROSPECTIVE STUDY;

EID: 0033980862     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.2.175     Document Type: Article

References (27)

1. Berk, S. L. & Kalbfleisch, J. H. (1996). Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in Western Europe and in the USA. Journal of Antimicrobial Chemotherapy 38, Suppl. A, 85-96.
2. Doern, G. V., Brueggemann, A. B., Pierce, G., Hogan, T., Holley, H. P., Jr & Rauch, A. (1996). Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrobial Agents and Chemotherapy 40, 2884-6.
3. Manninen, R., Huovinen, P. & Nissinen, A. (1997). Increasing antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Finland. Journal of Antimicrobial Chemotherapy 40, 387-92.
4. Wallace, R. J., Jr, Steingrube, V. A., Nash, D. R., Hollis, D. G., Flanagan, C., Brown, B. A. et al. (1989). BRO β-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal β-lactamase transfer by conjugation in B. catarrhalis, M. nonliquifaciens, and M. lacunata. Antimicrobial Agents and Chemotherapy 33, 1845-54.
5. Christensen, J. J., Keiding, J. & Bruun, B. (1990). Antimicrobial susceptibility and β-lactamase characterization of Branhamella catarrhalis isolates from 1983/1984 and 1988. Acta Pathologica, Microbiologica et Immunologica Scandinavica 98, 1039-44.
6. Ejlertsen, T. & Skov, R. (1996). The β-lactamase of Moraxella (Branhamella) catarrhalis isolated from Danish children. Acta Pathologica, Microbiologica et Immunologica Scandinavica 104, 557-62.
7. Fung, C. P., Jang, T. N., Liu, C. Y., Lau, Y. J., Liu, Y. C., Chuang, Y. C. et al. (1996). Antimicrobial susceptibility and β-lactamase production of Moraxella catarrhalis isolates in Taiwan. Journal of the Formosan Medical Association 94, 548-54.
8. Nash, D. R., Wallace, R. J., Jr, Steingrube, V. A. & Shurin, P. A. (1986). Isoelectric focusing of β-lactamases from sputum and middle ear isolates of Branhamella catarrhalis recovered in the United States. Drugs 31, Suppl. 3, 48-54.
9. McGregor, K., Chang, B. J., Mee, B. J. & Riley, T. V. (1998). Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO β-lactamases. European Journal of Clinical Microbiology and Infectious Disease 17, 219-34.
10. Robledano, L., Rivera, M. J., Otal, I. & Gomez-Lus, R. (1987). Enzymatic modification of aminoglycoside antibiotics by Branhamella catarrhalis carrying an R factor. Drugs under Experimental and Clinical Research 13, 137-43.
11. Baquero, F. (1996). Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study. Journal of Antimicrobial Chemotherapy 38, Suppl. A, 117-32.
12. Felmingham, D. & Grüneberg, R. N. (1996). A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993. The Alexander Project. Journal of Antimicrobial Chemotherapy 38, Suppl. A, 1-57.
13. Schwebke, J. R., Whittington, W., Rice, R. J., Handsfield, H. H., Hale, J. & Holmes, K. K. (1995). Trends in susceptibility of Neisseria gonorrhoeae to ceftriaxone from 1985 through 1991. Antimicrobial Agents and Chemotherapy 39, 917-20.
14. Thornsberry, C., Ogilvie, P. T., Holley, H. P., Jr & Sahm, D. F. (1998). In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: correlation with penicillin resistance. Clinical Therapeutics 20, 1179-90.
15. Walker, R. D. & Thornsberry, C. (1998). Decrease in antibiotic susceptibility or increase in resistance? Journal of Antimicrobial Chemotherapy 41, 1-4.
16. Gowan, A. & Bennett, P. (1998). Decrease in susceptibility or increase in resistance? - defects of present antimicrobial susceptibility surveillance. Journal of Antimicrobial Chemotherapy 42, 547-8.
17. SAS Institute, Inc. (1990). SAS/STAT User's Guide: Version 6, 4th edn. SAS Institute, Inc., Cary, NC.
18. Fung, C. P., Yeo, S. F. & Livermore, D. M. (1994). Susceptibility of Moraxella catarrhalis isolates to β-lactam antibiotics in relation to β-lactamase pattern. Journal of Antimicrobial Chemotherapy 33, 215-22.
19. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition: Approved Standard M7-A4. NCCLS, Villanova, PA.
20. Bootsma, H. J., van Dijk, H., Verhoef, J., Fleer, A. & Mooi, F. R. (1996). Molecular characterization of the BRO β-lactamase of Moraxella (Branhamella) catarrhalis. Antimicrobial Agents and Chemotherapy 40, 966-72.
21. Eliasson, I., Kamme, C. & Prellner, K. (1986). Beta-lactamase production in the upper respiratory tract flora. European Journal of Clinical Microbiology 5, 507-12.
22. Kaplan, N. L., Hudson, R. R. & Langley, C. H. (1989). The 'hitch-hiking effect' revisited. Genetics 123, 887-99.
23. Baquero, F., Negri, M. C., Morosini, M. I. & Blasquez, J. (1997). The antibiotic selective process: concentration-specific amplification of low-level resistant populations. In Antibiotic Resistance: Origins, Evolution, Selection and Spread (Chadwick, D. J. & Goode, J., Eds), pp. 93-111. Ciba Foundation Symposium 207. Wiley, New York.
24. Lenski, R. (1997). The cost of antibiotic resistance-from the perspective of a bacterium. In Antibiotic Resistance: Origins, Evolution, Selection and Spread (Chadwick, D. J. & Goode, J., Eds), pp. 131-51. Ciba Foundation Symposium 207. Wiley, New York.
25. Ison, C. A., Woodford, P. J., Madders, H. & Claydon, E. (1998). Drift in susceptibility of Neisseria gonorrhoeae to ciprofloxacin and emergence of therapeutic failure. Antimicrobial Agents and Chemotherapy 42, 2919-22.
26. Thornsberry, C. (1994). Susceptibility of clinical bacterial isolates to ciprofloxacin in the United States. Infection 22, Suppl. 2, S80-9.
27. Walker, E. S., Preston, R. A., Post, J. C., Ehrlich, G. D., Kalbfleisch, J. H. & Klingman, K. L. (1998). Genetic diversity of Moraxella catarrhalis: analysis using multiple DNA probes and a single-locus PCR-restriction fragment length polymorphism method. Journal of Clinical Microbiology 36, 1977-83.